64Cu-Labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity

Nuclear Medicine and Biology

Volumn 36, Issue 3, 2009, Pages 277-285

  Wei, Lihui ^a   Ye, Yunpeng ^a   Wadas, Thaddeus J ^a   Lewis, Jason S ^a   Welch, Michael J ^a,b,d   Achilefu, Samuel ^a,b,c   Anderson, Carolyn J ^a,b,c,d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY   (United States)

Author keywords

CB TE2A; Copper 64; Diamsar; RGD

Indexed keywords

CB TE2A RGDFD PEPTIDE CONJUGATE CU 64; CB TE2A RGDYK PEPTIDE CONJUGATE CU 64; CHELATING AGENT; DIAMSAR RGDFD PEPTIDE CONJUGATE CU 64; DIAMSAR RGDYK PEPTIDE CONJUGATE CU 64; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG SYNTHESIS; EXPERIMENTAL MOUSE; LIPOPHILICITY; MELANOMA; NONHUMAN;

ANIMALS; BINDING, COMPETITIVE; CHELATING AGENTS; DIPEPTIDES; HETEROCYCLIC COMPOUNDS; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MELANOMA; MICE; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; SARCOSINE; STAINING AND LABELING; TISSUE DISTRIBUTION;

EID: 62549139647     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.12.008     Document Type: Article

References (54)

1. Folkman J. Tumor angiogenesis. Adv Cancer Res 43 (1985) 175-203
2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 (2002) 15-18
3. Brower V. Tumor angiogenesis-new drugs on the block. Nat Biotechnol 17 (1999) 963-968
4. Brooks P.C., Clark R.A.F., and Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264 (1994) 569-571
5. Hwang R., and Varner J. The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am 18 (2004) 991-1006
6. Jin H., and Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 90 (2004) 561-565
7. Kumar C.C. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 4 (2003) 123-131
8. Brooks P.C., Montgomery A.M.P., Rosenfeld M., Reisfeld R.A., and Hu T. Integrin αvβ3 antagonists promote tumor-regression by inducing apoptosis of angiogenic blood vessels. Cell 79 (1994) 1157
9. Eliceiri B.P., and Cheresh D.A. The role of alpha v integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 103 (1999) 1227-1230
10. Tucker G.C. Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 4 (2003) 722-731
11. McQuade P., and Knight L.C. Radiopharmaceuticals for targeting the angiogenesis marker alpha(v)beta(3). Q J Nucl Med 47 (2003) 209-220
12. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 12 (1996) 697-715
13. Ruoslahti E., and Pierschbacher M.D. Arg-Gly-Asp - a versatile cell recognition signal. Cell 44 (1986) 517-518
14. Haubner R., and Wester H.J. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 10 (2004) 1439-1455
15. Haubner R.H., Wester H.J., Weber W.A., and Schwaiger M. Radiotracer-based strategies to image angiogenesis. Q J Nucl Med 47 (2003) 189-199
16. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin αvβ3 targeted radiotracers for tumor imaging. Mol Pharmacol 3 (2006) 472-487
17. Qaim S.M. Decay data and production yields of some non-standard positron emitters used in PET. Q J Nucl Med Mol Imaging 52 (2008) 111-120
18. Qaim S.M., Bisinger T., Hilgers K., Nayak D., and Coenen H.H. Positron emission intensities in the decay of 64Cu, 76Br and 124I. Radiochim Acta 95 (2007) 67-73
19. McCarthy D.W., Shefer R.E., Klinkowstein R.E., Bass L.A., Margeneau W.H., Cutler C.S., et al. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol 24 (1997) 35-43
20. Moi M.K., Meares C.F., McCall M.J., Cole W.C., and Denardo S.J. Copper-chelates as probes of biological-systems - stable copper-complexes with a macrocyclic bifunctional chelating agent. Anal Biochem 148 (1985) 249-253
21. Anderson C.J., Connett J.M., Schwarz S.W., Rocque P.A., Guo L.W., Philpott G.W., et al. Copper-64-labeled antibodies for PET imaging. J Nucl Med 33 (1992) 1685-1691
22. Jones-Wilson T.M., Deal K.A., Anderson C.J., McCarthy D.W., Kovacs Z., Motekaitis R.J., et al. The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl Med Biol 25 (1998) 523-530
23. Anderson C.J., Dehdashti F., Cutler P.D., Schwarz S.W., Laforest R., Bass L.A., et al. Cu-64-TETA-Octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 42 (2001) 213-221
24. Boswell C.A., Sun X., Niu W., Weisman G.R., Wong E.H., Rheingold A.L., et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 47 (2004) 1465-1474
25. Sun X., Wuest M., Weisman G.R., Wong E.H., Reed D.P., Boswell C.A., et al. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem 45 (2002) 469-477
26. Wong E.H., Weisman G.R., Hill D.C., Reed D.P., Rogers M.E., Condon J.S., et al. Synthesis and characterization of cross-bridged cyclams and pendant-armed derivatives and structural studies of their copper(II) complexes. J Am Chem Soc 122 (2000) 10561-10572
27. Sprague J.E., Peng Y., Sun X., Weisman G.R., Wong E.H., Achilefu S., et al. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res 10 (2004) 8674-8682
28. Wei L.H., Butcher C., Miao Y.B., Gallazzi F., Quinn T.P., Welch M.J., et al. Synthesis and biologic evaluation of Cu-64-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med 48 (2007) 64-72
29. Geue R.J., Hambley T.W., Harrowfield J.M., Sargeson A.M., and Snow M.R. Metal-ion encapsulation - cobalt cages derived from polyamines, formaldehyde, and nitromethane. J Am Chem Soc 106 (1984) 5478-5488
30. Smith S.V. Molecular imaging with copper-64. J Inorg Biochem 98 (2004) 1874-1901
31. Di Bartolo N.M., Sargeson A.M., Donlevy T.M., and Smith S.V. Synthesis of a new cage ligand, SarAr, and its complexation with selected transition metal ions for potential use in radioimaging. J Chem Soc-Dalton Trans (2001) 2303-2309
32. Bottomley G.A., Clark I.J., Creaser I.I., Engelhardt L.M., Geue R.J., Hagen K.S., et al. The synthesis and structure of encapsulating ligands - properties of bicyclic hexamines. Aust J Chem 47 (1994) 143-179
33. Sargeson A.M. The potential for the cage complexes in biology. Coord Chem Rev 151 (1996) 89-114
34. Voss S.D., Smith S.V., DiBartolo N., McIntosh L.J., Cyr E.M., Bonab A.A., et al. Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci U S A 104 (2007) 17489-17493
35. Di Bartolo N., Sargeson A.M., and Smith S.V. New Cu-64 PET imaging agents for personalised medicine and drug development using the hexa-aza cage, SarAr. Org Biomol Chem 4 (2006) 3350-3357
36. Sprague J.E., Kitaura H., Zou W., Ye Y., Achilefu S., Weilbaecher K.N., et al. Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide. J Nucl Med 48 (2007) 311-318
37. Haubner R., Wester H.J., Reuning U., Senekowitsch-Schmidtke R., Diefenbach B., Kessler H., et al. Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 40 (1999) 1061-1071
38. 99mTc-labelled cyclic RGD peptide for imaging the αvβ3 expression. Nuklearmedizin 43 (2004) 26-32
39. Tai Y.C., Ruangma A., Rowland D.J., Siegel S., Newport D.F., Chow P.L., et al. Performance evaluation of the microPET Focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 46 (2005) 455-463
40. Cheresh D.A., and Spiro R.C. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem 262 (1987) 17703-17711
41. Felding-Habermann B., Mueller B.M., Romerdahl C.A., and Cheresh D.A. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest 89 (1992) 2018-2022
42. Rogers B.E., Anderson C.J., Connett J.M., Guo L.W., Edwards W.B., Sherman E.L.C., et al. Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism. Bioconjug Chem 7 (1996) 511-522
43. Bass L.A., Wang M., Welch M.J., and Anderson C.J. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem 11 (2000) 527-532
44. Li W.P., Meyer L.A., Capretto D.A., Sherman C.D., and Anderson C.J. Receptor-binding, biodistribution, and metabolism studies of Cu-64-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm 23 (2008) 158-171
45. Anderson C.J., Jones L.A., Bass L.A., Sherman E.L.C., McCarthy D.W., Cutler P.D., et al. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J Nucl Med 39 (1998) 1944-1951
46. McQuade P., Miao Y.B., Yoo J., Quinn T.P., Welch M.J., and Lewis J.S. Imaging of melanoma using Cu-64- and Y-86-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. J Med Chem 48 (2005) 2985-2992
47. Weisman G.R., Wong E.H., Hill D.C., Rogers M.E., Reed D.P., and Calabrese J.C. Synthesis and transition-metal complexes of new cross-bridged tetraamine ligands. Chem Commun (1996) 947-948
48. Harrowfield J.M., Herlt A.J., Lay P.A., Sargeson A.M., Bond A.M., Mulac W.A., et al. Synthesis and properties of macrobicyclic amine complexes of rhodium(III) and iridium(III). J Am Chem Soc 105 (1983) 5503-5505
49. Bernhardt P.V., Bramley R., Engelhardt L.M., Harrowfield J.M., Hockless D.C.R., Korybutdaszkiewicz B.R., et al. Copper(II) complexes of substituted macrobicyclic hexaamines - combined trigonal and tetragonal distortions. Inorg Chem 34 (1995) 3589-3599
50. Comba P., Sargeson A.M., Engelhardt L.M., Harrowfield J.M., White A.H., Horn E., et al. Analysis of trigonal-prismatic and octahedral preferences in hexaamine cage complexes. Inorg Chem 24 (1985) 2325-2327
51. Pfaff M., Tangemann K., Muller B., Gurrath M., Muller G., Kessler H., et al. Selective recognition of cyclic RGD peptides of NMR defined conformation by αIIbβ3, αvβ3, and α5β1 integrins. J Biol Chem 269 (1994) 20233-20238
52. Haubner R., Gratias R., Diefenbach B., Goodman S.L., Jonczyk A., and Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin αvβ3 antagonists. J Am Chem Soc 118 (1996) 7461-7472
53. Wu Y., Zhang X.Z., Xiong Z.M., Cheng Z., Fisher D.R., Liu S., et al. microPET imaging of glioma integrin αvβ3 expression using Cu-64-labeled tetrameric RGD peptide. J Nucl Med 46 (2005) 1707-1718
54. Haubner R., Wester H.J., Burkhart F., Senekowitsch-Schmidtke R., Weber W., Goodman S.L., et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 42 (2001) 326-336